Jun Yue

Dr. Jun Yue

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2018 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
JYJun Yue
Jun Yue
RPRoger M. Pallares
Roger M. Pallares
LCLisa E. Cole
Lisa E. Cole
ECEmma E. Coughlin
Emma E. Coughlin
CMChad Mirkin
Chad Mirkin
TOTeri W. Odom
Teri W. Odom

26 June 2021 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
BDBinbin Ding
Binbin Ding
JYJun Yue
Jun Yue
PZPan Zheng
Pan Zheng
PMPing’aN Ma
Ping’aN Ma
Jun LinJun Lin
Jun Lin
Immunotherapy, a strategy that leverages the host immune function to fight against cancer, plays an increasingly important role in clinical tumor therapy. In spite of the great success achieved in not only clinical treatment but also basic research, cancer immunotherapy still faces many huge challenges. Manganese oxide nanomaterials (MONs), as ideal tumor microenvironment (TME)-responsive biomaterials, are able to dramatically elicit anti-tumor immune responses in multiple ways, indicating great prospects for immunotherapy. In this review, on the basis of different mechanisms to boost immunotherapy, major highlighted topics are presented, covering adjusting an immunosuppressive TME by generating O2 (like O2-sensitized photodynamic therapy (PDT), programmed cell death ligand-1 (PD-L1) expression downregulation, reprogramming tumor-associated macrophages (TAMs), and restraining tumor angiogenesis and lactic acid exhaustion), inducing immunogenic cell death (ICD), photothermal therapy (PTT) induction, activating the stimulator of interferon gene (STING) pathway and immunoadjuvants for nanovaccines. We hope that this review will provide holistic understanding about MONs and their application in cancer immunotherapy, and thus pave the way to the translation from bench to bedside in the future.

12 June 2021 in Bioactive Materials
Verified
Journal Article
Open access
LWLei Wu
Lei Wu
WZWenhui Zhou
Wenhui Zhou
LLLihua Lin
Lihua Lin
ACAnhong Chen
Anhong Chen
JFJing Feng
Jing Feng
JYJun Yue
Jun Yue
Therapeutic oligonucleotides (TOs) represent one of the most promising drug candidates in the targeted cancer treatment due to their high specificity and capability of modulating cellular pathways that are not readily druggable. However, efficiently delivering of TOs to cancer cellular targets is still the biggest challenge in promoting their clinical translations. Emerging as a significant drug delivery vector, nanoparticles (NPs) can not only protect TOs from nuclease degradation and enhance their tumor accumulation, but also can improve the cell uptake efficiency of TOs as well as the following endosomal escape to increase the therapeutic index. Furthermore, targeted and on-demand drug release of TOs can also be approached to minimize the risk of toxicity towards normal tissues using stimuli-responsive NPs. In the past decades, remarkable progresses have been made on the TOs delivery based on various NPs with specific purposes. In this review, we will first give a brief introduction on the basis of TOs as well as the action mechanisms of several typical TOs, and then describe the obstacles that prevent the clinical translation of TOs, followed by a comprehensive overview of the recent progresses on TOs delivery based on several various types of nanocarriers containing lipid-based nanoparticles, polymeric nanoparticles, gold nanoparticles, porous nanoparticles, DNA/RNA nanoassembly, extracellular vesicles, and imaging-guided drug delivery nanoparticles.

21 April 2022 in Small
Verified
Journal Article
Closed access
ACAnhong Chen
Anhong Chen
LWLei Wu
Lei Wu
YLYao Luo
Yao Luo
SLShaojin Lu
Shaojin Lu
YWYupeng Wang
Yupeng Wang
JYJun Yue
Jun Yue

17 March 2022 in ACS Macro Letters
Verified
Journal Article
Closed access
ZCZhenhua Cui
Zhenhua Cui
YFYanwen Feng
Yanwen Feng
FLFei Liu
Fei Liu
Lelun JiangLelun Jiang
Lelun Jiang
JYJun Yue
Jun Yue

6 July 2020 in ACS Applied Polymer Materials
Verified
Journal Article
Closed access
JYJun Yue
Jun Yue
LHLanqi He
Lanqi He
PZPei Zhao
Pei Zhao
YGYi Gu
Yi Gu